FOKEXA Trademark

Trademark Overview

On Tuesday, September 13, 2011, a trademark application was filed for FOKEXA with the United States Patent and Trademark Office. The USPTO has given the FOKEXA trademark a serial number of 85421308. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, November 10, 2014. This trademark is owned by ENDOCYTE, INC.. The FOKEXA trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for the treatment and diagnosis of oncological and inflammatory disorders
fokexa

General Information

Serial Number85421308
Word MarkFOKEXA
Filing DateTuesday, September 13, 2011
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, November 10, 2014
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, August 14, 2012

Trademark Statements

Goods and ServicesPharmaceutical preparations for the treatment and diagnosis of oncological and inflammatory disorders

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateFriday, September 16, 2011
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameENDOCYTE, INC.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressWest Lafayette, IN 47906
Party NameENDOCYTE, INC.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressWest Lafayette, IN 47906

Trademark Events

Event DateEvent Description
Monday, November 10, 2014ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILED
Monday, November 10, 2014ABANDONMENT - NO USE STATEMENT FILED
Wednesday, April 16, 2014NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, April 15, 2014EXTENSION 3 GRANTED
Tuesday, April 8, 2014EXTENSION 3 FILED
Tuesday, April 8, 2014TEAS EXTENSION RECEIVED
Friday, October 11, 2013NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, October 10, 2013EXTENSION 2 GRANTED
Monday, October 7, 2013EXTENSION 2 FILED
Monday, October 7, 2013TEAS EXTENSION RECEIVED
Wednesday, May 15, 2013NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, May 14, 2013EXTENSION 1 GRANTED
Tuesday, April 9, 2013EXTENSION 1 FILED
Friday, May 10, 2013CASE ASSIGNED TO INTENT TO USE PARALEGAL
Friday, April 19, 2013NOTICE OF REVIVAL - E-MAILED
Thursday, April 18, 2013EXTENSION RECEIVED WITH TEAS PETITION
Thursday, April 18, 2013PETITION TO REVIVE-GRANTED
Thursday, April 18, 2013TEAS PETITION TO REVIVE RECEIVED
Tuesday, October 9, 2012NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, August 14, 2012OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, August 14, 2012PUBLISHED FOR OPPOSITION
Wednesday, July 25, 2012NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Friday, July 6, 2012LAW OFFICE PUBLICATION REVIEW COMPLETED
Friday, July 6, 2012ASSIGNED TO LIE
Monday, June 18, 2012TEAS CHANGE OF CORRESPONDENCE RECEIVED
Monday, June 18, 2012APPROVED FOR PUB - PRINCIPAL REGISTER
Monday, June 18, 2012TEAS/EMAIL CORRESPONDENCE ENTERED
Monday, June 18, 2012CORRESPONDENCE RECEIVED IN LAW OFFICE
Monday, June 18, 2012TEAS RESPONSE TO OFFICE ACTION RECEIVED
Friday, December 30, 2011NOTIFICATION OF NON-FINAL ACTION E-MAILED
Friday, December 30, 2011NON-FINAL ACTION E-MAILED
Friday, December 30, 2011NON-FINAL ACTION WRITTEN
Thursday, December 29, 2011ASSIGNED TO EXAMINER
Friday, September 16, 2011NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Friday, September 16, 2011NEW APPLICATION ENTERED IN TRAM

Related Keywords

fokexa inflammatory disorders oncological diagnosis preparations treatment pharmaceutical